Upstream Bio (NASDAQ:UPB) Upgraded to “Strong-Buy” at HC Wainwright

Posted by Brian Himes on Jun 4th, 2026

HC Wainwright upgraded shares of Upstream Bio (NASDAQ:UPB – Free Report) to a strong-buy rating in a research note published on Wednesday morning,Zacks.com reports.

A number of other equities research analysts have also recently commented on the stock. Evercore cut shares of Upstream Bio from an “outperform” rating to an “in-line” rating and set a $15.00 price objective on the stock. in a research note on Friday, March 27th. Wall Street Zen cut shares of Upstream Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings cut shares of Upstream Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Finally, Mizuho dropped their price target on shares of Upstream Bio from $51.00 to $50.00 and set an “outperform” rating on the stock in a research note on Thursday, May 14th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Upstream Bio currently has an average rating of “Moderate Buy” and a consensus price target of $38.20.

View Our Latest Stock Report on Upstream Bio

Upstream Bio Price Performance

Shares of NASDAQ UPB opened at $7.63 on Wednesday. The stock has a market capitalization of $415.22 million, a price-to-earnings ratio of -2.62 and a beta of 1.10. Upstream Bio has a 12 month low of $7.18 and a 12 month high of $33.68. The firm’s 50 day simple moving average is $9.12 and its 200-day simple moving average is $17.70.

Upstream Bio (NASDAQ:UPB – Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.02). The firm had revenue of $1.03 million for the quarter, compared to analyst estimates of $1.03 million. Upstream Bio had a negative return on equity of 43.82% and a negative net margin of 4,718.96%. Analysts anticipate that Upstream Bio will post -2.99 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Upstream Bio

A number of institutional investors have recently added to or reduced their stakes in UPB. Integral Health Asset Management LLC acquired a new stake in Upstream Bio during the 3rd quarter worth $10,816,000. Jennison Associates LLC acquired a new stake in Upstream Bio during the 4th quarter worth $7,842,000. Pictet Asset Management Holding SA acquired a new position in Upstream Bio during the fourth quarter worth about $20,991,000. UBS Group AG grew its stake in Upstream Bio by 563.4% during the 4th quarter. UBS Group AG now owns 1,806,243 shares of the company’s stock valued at $49,039,000 after acquiring an additional 1,533,972 shares in the last quarter. Finally, Strs Ohio purchased a new stake in Upstream Bio during the 4th quarter valued at about $266,000.

Upstream Bio Company Profile

(Get Free Report)

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.